Trial Profile
Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir based regimens.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2013
Price :
$35
*
At a glance
- Drugs Atazanavir/ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms CRISTAL
- 04 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
- 04 Mar 2013 Status changed from recruiting to completed.
- 05 Aug 2011 New trial record